AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML)-Reference-Cited by-同舟云学术

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML)

Published:2005-06 Issue:16_suppl Volume:23 Page:3014-3014
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Kantarjian H.¹,Ottmann O.¹,Cortes J.¹,Wassmann B.¹,Jones D.¹,Hochhaus A.¹,Alland L.¹,Dugan M.¹,Albitar M.¹,Giles F.¹

Affiliation:

1. UT M.D. Anderson Cancer Ctr, Houston, TX; J. W. Goethe Univ, Frankfurt, Germany; Univ Heidelberg, Mannheim, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Quest Diagnostics, San Juan Capistrano, CA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2005.23.16_suppl.3014

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells;Cancers;2020-04-09

2. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling;Journal of Cellular and Molecular Medicine;2008-01-11

3. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study;Blood;2007-06-01

4. Improving upon the promise of targeted therapy of human malignancy: chronic myeloid leukemia as a paradigm;Cancer Chemotherapy and Pharmacology;2006-11

5. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations;Blood;2006-10-01